Asset Details
Do you wish to reserve the book?
Comparative study of nonmotor symptoms in progressive supranuclear palsy and Parkinson’s disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative study of nonmotor symptoms in progressive supranuclear palsy and Parkinson’s disease
Do you wish to request the book?
Comparative study of nonmotor symptoms in progressive supranuclear palsy and Parkinson’s disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative study of nonmotor symptoms in progressive supranuclear palsy and Parkinson’s disease
2025
Overview
Background
Nonmotor symptoms (NMSs) are under-recognized in progressive supranuclear palsy (PSP), despite their considerable impact on quality of life. The full spectrum and impact of NMSs in PSP remain insufficiently understood. This study is aimed to investigate NMSs in patients with PSP and compare the difference of NMSs between patients with PSP and patients with Parkinson’s disease (PD).
Methods
The study involved 44 patients diagnosed with PSP and 132 patients with PD. NMSs were assessed using a range of evaluation tools. Additionally, the relationship between NMSs and disease severity, as well as the impact on quality of life was analyzed.
Results
The Non-Motor Symptom Scale (NMSS) and Movement Disorders Society-revised Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I scores were significantly higher in patients with PSP than in patients with PD (42.52 ± 25.64 vs. 32.06 ± 21.45,
p
= 0.007; 11.89 ± 6.24 vs. 9.80 ± 5.61,
p
= 0.049). The severity of urinary symptoms was also greater in patients with PSP than in those with PD. Although clinically suspected rapid eye movement sleep behavior disorder (RBD), which was not assessed using polysomnography but rather through RBD Screening Questionnaire, was less common in patients with PSP compared with those with PD, cognitive impairment was more frequent and severe in patients with PSP. Hyposmia, cardiovascular symptoms, constipation, sleep disturbances, emotional symptoms, fatigue, and pain exhibited similar severity and frequency in both patient groups. Only emotional symptoms in patients with PSP were associated with the 39-item Parkinson’s Disease Questionnaire scores, and none of the NMSs were associated with Hoehn & Yahr stage or MDS-UPDRS Part III scores.
Conclusion
PSP is characterized by a higher burden of NMSs than PD, with some different and common symptom profiles. The impact of emotional symptoms on the quality of life in PSP underscores the importance of addressing these symptoms in clinical care to improve patient outcomes.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Anxiety
/ Diseases
/ Emotions
/ Fatigue
/ Female
/ Humans
/ Male
/ Medicine
/ Memory
/ Parkinson Disease - complications
/ Parkinson Disease - diagnosis
/ Parkinson Disease - physiopathology
/ Parkinson Disease - psychology
/ Progressive supranuclear palsy
/ REM Sleep Behavior Disorder - etiology
/ Sleep Wake Disorders - etiology
/ Supranuclear Palsy, Progressive - complications
/ Supranuclear Palsy, Progressive - diagnosis
/ Supranuclear Palsy, Progressive - physiopathology
